Maria Stepanova

Hivatkozott rá

	Összes	2019 óta
Hivatkozások	17527	10303
h-index	60	47
i10-index	171	144

2100

1050

525

1575

200920102011201220132014201520162017201820192020202120222023202472 128 236 337 429 645 856 1121 1310 1805 1728 1789 1986 1988 2028 764

Nyilvános hozzáférés

Összes megtekintése

12 cikk

2 cikk

elérhető

nem érhető el

Finanszírozási megbízások alapján

Társszerzők

Zobair YounossiThe Global NASH CouncilE-mail megerősítve itt: cldq.org
Zachary GoodmanInova Fairfax Medical CampusE-mail megerősítve itt: inova.org
Ancha Baranova, Анча БарановаProfessor, School of Systems Biology, George Mason UniversityE-mail megerősítve itt: gmu.edu
Aybike BirerdincResearch Assistant Professor, George Mason UniversityE-mail megerősítve itt: gmu.edu
Pegah GolabiDoctor of Medicine, Betty and Guy Beatty Center for Integrated Research, Inova Health System, FallsE-mail megerősítve itt: inova.org
Vikas ChandhokeGeorge Mason UniversityE-mail megerősítve itt: gmu.edu
Michael EstepScientist, Inova Health SystemE-mail megerősítve itt: inova.org
Janus OngAssociate Professor, University of the Philippines College of MedicineE-mail megerősítve itt: up.edu.ph
Vincent Wai-Sun WongThe Chinese University of Hong KongE-mail megerősítve itt: mect.cuhk.edu.hk
Prof Dr Yusuf YılmazRecep Tayyip Erdogan UniversityE-mail megerősítve itt: marmara.edu.tr
Jillian Kallman Price, PhDBetty & Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA.E-mail megerősítve itt: inova.org
Ajay DusejaHepatology, PGIMER, ChandigarhE-mail megerősítve itt: pgimer.edu.in
Saleh A AlqahtaniKing Faisal Specialist Hospital and Research CentreE-mail megerősítve itt: jhmi.edu
Nezam AfdhalProfessor of Medicine, Harvard Medical SchoolE-mail megerősítve itt: bidmc.harvard.edu
Professor Mohammed H. JarrarProfessor of Medical Biotechnology, Senior Manager of Medical & Health Research, QNRF, QATARE-mail megerősítve itt: qnrf.org
Kris KowdleyDirector, Liver Institute NorthwestE-mail megerősítve itt: liverinstitutenw.org
Francesco NegroProfessor, University Hospitals of GenevaE-mail megerősítve itt: hcuge.ch
Mark S. Sulkowski, MDProfessor of Medicine; Johns Hopkins University School of MedicineE-mail megerősítve itt: jhmi.edu
Leyla AvilaE-mail megerősítve itt: yorkmail.cuny.edu
Manuel Romero-GómezCatedrático de Medicina, Universidad de Sevilla.E-mail megerősítve itt: us.es

Követés

Maria Stepanova

Director of Statistical Services, COR-LD

E-mail megerősítve itt: cldq.org

metabolic diseases clinical trials


Cím Rendezés hivatkozások szerint Rendezés év szerint Rendezés cím szerint	Hivatkozott rá Hivatkozott rá	Év
Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008 ZM Younossi, M Stepanova, M Afendy, Y Fang, Y Younossi, H Mir, ... Clinical gastroenterology and hepatology 9 (6), 524-530. e1, 2011	1425	2011
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe ZM Younossi, D Blissett, R Blissett, L Henry, M Stepanova, Y Younossi, ... Hepatology 64 (5), 1577-1586, 2016	1251	2016
Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver‐related mortality ZM Younossi, M Stepanova, N Rafiq, H Makhlouf, Z Younoszai, ... Hepatology 53 (6), 1874-1882, 2011	708	2011
Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates Z Younossi, M Stepanova, JP Ong, IM Jacobson, E Bugianesi, A Duseja, ... Clinical gastroenterology and hepatology 17 (4), 748-755. e3, 2019	668	2019
Nonalcoholic fatty liver disease in lean individuals in the United States ZM Younossi, M Stepanova, F Negro, S Hallaji, Y Younossi, B Lam, ... Medicine 91 (6), 319-327, 2012	627	2012
Adipokines and cytokines in non‐alcoholic fatty liver disease MH Jarrar, A Baranova, R Collantes, B Ranard, M Stepanova, C Bennett, ... Alimentary pharmacology & therapeutics 27 (5), 412-421, 2008	619	2008
Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden Z Younossi, H Park, L Henry, A Adeyemi, M Stepanova Gastroenterology 150 (7), 1599-1608, 2016	458	2016
Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population M Stepanova, ZM Younossi Clinical Gastroenterology and Hepatology 10 (6), 646-650, 2012	425	2012
Epidemiology of chronic liver diseases in the USA in the past three decades ZM Younossi, M Stepanova, Y Younossi, P Golabi, A Mishra, N Rafiq, ... Gut 69 (3), 564-568, 2020	403	2020
Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease N Hossain, A Afendy, M Stepanova, F Nader, M Srishord, N Rafiq, ... Clinical Gastroenterology and Hepatology 7 (11), 1224-1229. e2, 2009	390	2009
Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study M Stepanova, N Rafiq, ZM Younossi Gut 59 (10), 1410-1415, 2010	358	2010
Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States ZM Younossi, M Stepanova, J Ong, G Trimble, S AlQahtani, I Younossi, ... Clinical Gastroenterology and Hepatology 19 (3), 580-589. e5, 2021	345	2021
A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH) ZM Younossi, M Jarrar, C Nugent, M Randhawa, M Afendy, M Stepanova, ... Obesity surgery 18, 1430-1437, 2008	343	2008
Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD) M Stepanova, N Rafiq, H Makhlouf, R Agrawal, I Kaur, Z Younoszai, ... Digestive diseases and sciences 58, 3017-3023, 2013	315	2013
In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009 M Stepanova, A Mishra, C Venkatesan, ZM Younossi Clinical gastroenterology and hepatology 10 (9), 1034-1041. e1, 2012	277	2012
Non‐alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population‐based study L Gerber, M Otgonsuren, A Mishra, C Escheik, A Birerdinc, M Stepanova, ... Alimentary pharmacology & therapeutics 36 (8), 772-781, 2012	241	2012
NASH in lean individuals R Younes, E Bugianesi Seminars in liver disease 39 (01), 086-095, 2019	230	2019
Predictors of health‐related quality of life in patients with chronic liver disease A Afendy, JB Kallman, M Stepanova, Z Younoszai, RD Aquino, G Bianchi, ... Alimentary pharmacology & therapeutics 30 (5), 469-476, 2009	204	2009
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir ZM Younossi, M Stepanova, N Afdhal, KV Kowdley, S Zeuzem, L Henry, ... Journal of hepatology 63 (2), 337-345, 2015	193	2015
Caffeine is protective in patients with non‐alcoholic fatty liver disease A Birerdinc, M Stepanova, L Pawloski, ZM Younossi Alimentary pharmacology & therapeutics 35 (1), 76-82, 2012	191	2012

A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.

Cikkek 1–20

Hivatkozások évente

Ismétlődő hivatkozások

Összevont hivatkozások

Társszerzők hozzáadásaTársszerzők

Követés

Hivatkozott rá

Társszerzők